What is the difference between Aniracetam and Oxiracetam?

Aniracetam: Aniracetam is a non-peptide pyrrolidinone derivative and positive allosteric modulator of AMPA-type glutamate receptors. It is marketed as a prescription drug for cognitive disorders in some European ... Oxiracetam: Oxiracetam is a non-peptide racetam-class cognitive enhancer, structurally the 4-hydroxy analog of piracetam. It is approved as a prescription drug for dementia in Italy (since 1984) and China, but is...

What does the research say about Aniracetam vs Oxiracetam?

Aniracetam: The principal human efficacy evidence is one 6-month, double-blind, placebo-controlled multicenter trial in 109 elderly patients meeting probable-Alzheimer's criteria, which showed significant improvement in psychobehavioral parameters versus placebo with excellent reported tolerability, though no itemized adverse-event breakdown was available. No… Oxiracetam: Multiple placebo-controlled human trials exist in dementia, organic brain syndrome, and traumatic brain injury populations, plus human pharmacokinetic studies. One double-blind controlled trial in elderly organic-brain-syndrome patients used doses titrated from 400–2400 mg/day; a separate placebo-controlled trial in senile dementia of Alzheimer typ…

Aniracetam vs Oxiracetam

Q: Can you stack Aniracetam and Oxiracetam?

Aniracetam (cognitive) and Oxiracetam (cognitive) are in the same category and may have overlapping mechanisms — researchers should review both profiles carefully before combining. Consult a licensed provider before combining any compounds.

Head-to-head comparison of Aniracetam and Oxiracetam — mechanism, side effects, legal status, and pricing.

Aniracetam

Aniracetam is a non-peptide pyrrolidinone derivative and positive allosteric modulator of AMPA-type glutamate receptors. It is marketed as a prescription drug for cognitive disorders in some European countries (Italy, Greece) but has never been approved by the US FDA as either a drug or dietary supplement ingredient. The compound was reportedly withdrawn from the Japanese market following a failed confirmatory trial. Despite lacking US regulatory approval, aniracetam is openly sold online by nootropic-supplement retailers, often with significant label-accuracy problems.

Profile Prices Testing

Oxiracetam

Oxiracetam is a non-peptide racetam-class cognitive enhancer, structurally the 4-hydroxy analog of piracetam. It is approved as a prescription drug for dementia in Italy (since 1984) and China, but is NOT FDA-approved in the United States. The FDA has classified oxiracetam as a 'new drug' requiring approval and determined it does not qualify as a dietary supplement; in the US it is sold only as an unregulated gray-market research chemical.

Profile Prices Testing

Aniracetam

Oxiracetam

Category

Cognitive

Legal Status

Research Only

Mechanism

Aniracetam is a positive allosteric modulator of AMPA-type ionotropic glutamate receptors. X-ray crystallographic and electrophysiological work on the GluA2 ligand-binding domain demonstrates that aniracetam binds at the dimer interface, on the twofold axis of molecular symmetry, adjacent to the hinge of the clamshell-like ligand-binding core. This binding stabilizes the closed-cleft, glutamate-bound conformation and slows receptor deactivation and desensitization, a mechanism distinct from piracetam's binding site.

Proposed mechanism (not fully established in humans) is positive modulation of AMPA-type glutamate receptors: in rat cortical synaptic membranes and cultured neurons, oxiracetam enhanced AMPA-stimulated calcium influx and modulated AMPA binding without affecting kainate or NMDA signaling. Separate preclinical work found oxiracetam increases depolarization-evoked acetylcholine, glutamate, and aspartate release from rat hippocampal slices (not synaptosomes), with in vivo microdialysis showing ~63% increase in hippocampal acetylcholine release at 100 mg/kg in rats. No human receptor-occupancy or mechanistic imaging data were found.

Side Effects

Tolerability reported as 'excellent' in one 6-month trial, but no itemized adverse-event data available
No long-term (multi-year) human safety data located
Regulatory withdrawal in Japan following failed confirmatory trial suggests inconsistent efficacy/safety signal

Where Researchers Are Buying

Live · updated daily

COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower

Aniracetam

No pricing data yet.

Check Aniracetam prices →

Oxiracetam

No pricing data yet.

Check Oxiracetam prices →

Lab Verification

COA corpus from Disclosed Labs — independently tested batches only.

Aniracetam

COAs

99.5%

Avg purity

Labs

Full testing data

Oxiracetam

COAs

99.4%

Avg purity

Labs

Full testing data

Aniracetam Research Summary

The principal human efficacy evidence is one 6-month, double-blind, placebo-controlled multicenter trial in 109 elderly patients meeting probable-Alzheimer's criteria, which showed significant improvement in psychobehavioral parameters versus placebo with excellent reported tolerability, though no itemized adverse-event breakdown was available. No long-term (multi-year) human safety data were located, and no interventional trials of aniracetam are currently registered on ClinicalTrials.gov. In rodent models, aniracetam (50 mg/kg/day for 10 postnatal days) reversed prenatal-ethanol-induced avoidance-learning deficits in rat offspring and increased AMPA-receptor-mediated synaptic currents in hippocampal CA1 pyramidal cells. However, oral aniracetam (50 mg/kg, 5 days/week for 6 weeks) produced no cognitive or behavioral enhancement in healthy adult C57BL/6J mice across a comprehensive test battery.

Key references

Oxiracetam Research Summary

Multiple placebo-controlled human trials exist in dementia, organic brain syndrome, and traumatic brain injury populations, plus human pharmacokinetic studies. One double-blind controlled trial in elderly organic-brain-syndrome patients used doses titrated from 400–2400 mg/day; a separate placebo-controlled trial in senile dementia of Alzheimer type and multi-infarct dementia used 800 mg twice daily and reported improvement on cognitive measures versus placebo. Preclinical findings include AMPA receptor modulation and enhanced neurotransmitter release in rat hippocampal preparations, and identification of the (S)-enantiomer as the active component alleviating cognitive impairment in a rat chronic cerebral hypoperfusion model. Oral bioavailability in humans is ~56% (versus 28–42% in rats, 81–90% in dogs), with predominantly renal excretion of unchanged drug.

Can you stack Aniracetam and Oxiracetam?

Aniracetam and Oxiracetam are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.

Other comparisons

Aniracetam vs Piracetam Oxiracetam vs Piracetam Aniracetam vs Pramiracetam Aniracetam vs Nefiracetam Aniracetam vs Coluracetam Aniracetam vs Fasoracetam Aniracetam vs Phenylpiracetam hydrazide Aniracetam vs Sunifiram

This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.